Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Mekinist®
( trametinib )Oncology -
Myfortic®
( mycophenolic acid (as mycophenolate sodium) )Immunology and Dermatology -
Neoral®/Sandimmune®
( cyclosporine, USP Modified )Immunology and Dermatology -
NETSPOT®
( gallium Ga 68 dotatate injection )Advanced Accelerator ApplicationsAvailable in -
Onbrez® Breezhaler®
( indacaterol )Respiratory -
Piqray®
( alpelisib )Oncology -
Pluvicto™
( lutetium Lu 177 vipivotide tetraxetan )Advanced Accelerator ApplicationsAvailable in